Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...4567891011121314...143144»
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Lenvatinib  (JW Marriott Desert Ridge Grand Canyon 6-8; Poster Screen #4) -  Jan 24, 2024 - Abstract #MHNCS2024MHNCS_193;    
    P2
    Patients will be randomly assigned 3:3:2 to receive oral lenvatinib 20 mg once daily plus pembrolizumab 200 mg IV every 3 weeks (?35 pembrolizumab cycles), standard-of-care chemotherapy (investigator
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, Metastases:  Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. (Pubmed Central) -  Jan 23, 2024   
    Ongoing clinical trials have continued to uncover innovative cetuximab-based treatment strategies, promising a brighter future for mCRC patients. This review provides a comprehensive overview of cetuximab's role and its evolving importance in personalized targeted therapy of mCRC patients, offering valuable insights into the evolving landscape of colorectal cancer treatment.
  • ||||||||||  garsorasib (D-1553) / InventisBio
    Trial primary completion date, Metastases:  KEYNOTE-C15: Study to Evaluate D-1553 in Subjects With Solid Tumors (clinicaltrials.gov) -  Jan 23, 2024   
    P1/2,  N=200, Active, not recruiting, 
    This review provides a comprehensive overview of cetuximab's role and its evolving importance in personalized targeted therapy of mCRC patients, offering valuable insights into the evolving landscape of colorectal cancer treatment. Trial primary completion date: Sep 2023 --> Apr 2024
  • ||||||||||  Enrollment closed, Enrollment change:  MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer (clinicaltrials.gov) -  Jan 18, 2024   
    P=N/A,  N=46, Active, not recruiting, 
    The proposed fine-tuning workflow could be feasibly adopted to implement an accurate and robust auto-segmentation model by using local datasets and external public datasets. Recruiting --> Active, not recruiting | N=180 --> 46
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
    Preclinical, Journal:  Exploring the Sensitivity of Antibody-Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line. (Pubmed Central) -  Jan 18, 2024   
    Panitumumab, which had the second-highest anti-EGFR affinity, exhibited the least effective cytolysis across A431, A549, and MDA-MB-231 cells. By demonstrating that ADC potency toward a given target is dependent on both the antibody and drug chosen, these findings can guide the selection of ADCs for further in vivo analysis.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Dual-Function Antibody Conjugate-Enabled Photoimmunotherapy Complements Fluorescence and Photoacoustic Imaging of Head and Neck Cancer Spheroids. (Pubmed Central) -  Jan 18, 2024   
    The DFAC reported previously and used in the present study comprises an EGFR-targeted antibody, cetuximab, conjugated to benzoporphyrin derivative (BPD) for fluorescence imaging and PIT and a Si-centered naphthalocyanine dye for photoacoustic imaging...Together our results demonstrate the complementary imaging and treatment capacity of DFAC. This potentially enables fluorescence imaging to assess the presence of tumor on a macroscopic scale, followed by photoacoustic imaging for delineating tumor margins guiding surgical resection and elimination of any residual microscopic disease by PIT, in a single intraoperative setting.
  • ||||||||||  CIML NK - Dana / Farber Cancer Institute
    Trial completion date, Trial primary completion date, Combination therapy, Metastases, Immune cell:  CIML NK Cell in Head & Neck Cancer (clinicaltrials.gov) -  Jan 17, 2024   
    P1,  N=25, Recruiting, 
    This potentially enables fluorescence imaging to assess the presence of tumor on a macroscopic scale, followed by photoacoustic imaging for delineating tumor margins guiding surgical resection and elimination of any residual microscopic disease by PIT, in a single intraoperative setting. Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    MODULE 4: Integration of Immune Checkpoint Inhibitors into the Management of MSI-High/MMR-Deficient Mcrc (Golden Gate Ballroom ) -  Jan 16, 2024 - Abstract #ASCOGI2024ASCO_GI_936;    
    This activity is supported by educational grants from Natera Inc and Pfizer Inc. Similarities and differences between BRAF V600E and non-V600 mutations in mCRC; implications for disease management Potential clinical or biological factors, such as patient characteristics, tumor sidedness, histology and co-mutations, associated with the presence of BRAF V600 mutations in CRC Long-term findings from the Phase III BEACON CRC study evaluating encorafenib/cetuximab with or without binimetinib versus standard therapy for patients with mCRC and BRAF V600E mutations FDA approval and appropriate integration of encorafenib/cetuximab for patients with BRAF V600E-mutated mCRC Rationale for the evaluation of earlier use of BRAF-targeted therapy; findings from the Phase II ANCHOR CRC trial evaluating encorafenib/binimetinib/cetuximab for patients with treatment-na
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal, PD(L)-1 Biomarker:  EPIGENETIC ALTERATIONS DRIVING ONCOGENESIS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA. (Pubmed Central) -  Jan 12, 2024   
    Cetuximab, which targets the epidermal growth factor receptor, and pembrolizumab, an anti-programmed-death ligand 1 antibody, are among few FDA-approved medications. Current therapies are poor and cause severe long-term toxicity, which has a long-term impact on the quality of life [1].......
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer. (Pubmed Central) -  Jan 11, 2024   
    Additionally, HAI-1, an endogenous inhibitor of HGF proteases, (i) was downregulated in CRC, (ii) exhibited increased genomic methylation that correlated with poor prognosis, (iii) HAI-1 expression correlated with cetuximab response in a panel of cancer cell lines, and (iv) exogenous addition of recombinant HAI-1 overcame cetuximab resistance in CC-HGF cells. Thus, we describe a targetable, autocrine HAI-1/Protease/HGF/MET axis in cetuximab resistance in CRC.
  • ||||||||||  TTX-080 / Tizona Therap
    Phase classification, Combination therapy, Monotherapy, Metastases:  TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov) -  Jan 9, 2024   
    P1,  N=240, Active, not recruiting, 
    The hypothesized benefit of concomitant treatment with cetuximab over cisplatin regarding the prevalence of malnutrition was not supported by this study. Phase classification: P1a/1b --> P1
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Journal:  HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies. (Pubmed Central) -  Jan 9, 2024   
    In this study, we found amplification of the rare oncogenic KRASP34R was not only associated with an aggressive phenotype, but also supported cancer resistance to cetuximab, chemotherapy, and immunotherapy. Our findings indicate that pan-HER inhibition including HER4 and EGFR blockade is more effective than selectively targeting HER3 or HER2-HER3 in NRG1 fusion-positive cancers.
  • ||||||||||  garsorasib (D-1553) / InventisBio
    Enrollment closed, Trial primary completion date, Metastases:  KEYNOTE-C15: Study to Evaluate D-1553 in Subjects With Solid Tumors (clinicaltrials.gov) -  Jan 8, 2024   
    P1/2,  N=200, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2024 --> Sep 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date:  Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) -  Jan 3, 2024   
    P2,  N=74, Active, not recruiting, 
    PFS and OS were significantly prolonged in those patients who experienced a decrease of S100A8 compared with those patients who experienced increase of plasma S100A8 at three months. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    MODULE 3: Identification and Clinical Care of Patients with mCRC and a BRAF V600E Mutation (Golden Gate Ballroom ) -  Jan 2, 2024 - Abstract #ASCOGI2024ASCO_GI_913;    
    This activity is supported by educational grants from Natera Inc and Pfizer Inc. Similarities and differences between BRAF V600E and non-V600 mutations in mCRC; implications for disease management Potential clinical or biological factors, such as patient characteristics, tumor sidedness, histology and co-mutations, associated with the presence of BRAF V600 mutations in CRC Long-term findings from the Phase III BEACON CRC study evaluating encorafenib/cetuximab with or without binimetinib versus standard therapy for patients with mCRC and BRAF V600E mutations FDA approval and appropriate integration of encorafenib/cetuximab for patients with BRAF V600E-mutated mCRC Rationale for the evaluation of earlier use of BRAF-targeted therapy; findings from the Phase II ANCHOR CRC trial evaluating encorafenib/binimetinib/cetuximab for patients with treatment-na
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Review, Journal, Metastases:  The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer. (Pubmed Central) -  Jan 2, 2024   
    Further investigation of biomarkers may allow patient selection for those who could benefit from anti-EGFR mAbs in combination with EGFR-TKIs. This review summarizes findings of recent studies of anti-EGFR mAbs in combination with EGFR-TKIs for the treatment of patients with EGFR-mutated NSCLC, as well as clinical evidence for potential biomarkers towards personalized targeted medicine.
  • ||||||||||  INCB161734 / Incyte
    Enrollment open, Metastases:  A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (clinicaltrials.gov) -  Jan 2, 2024   
    P1,  N=322, Recruiting, 
    This review summarizes findings of recent studies of anti-EGFR mAbs in combination with EGFR-TKIs for the treatment of patients with EGFR-mutated NSCLC, as well as clinical evidence for potential biomarkers towards personalized targeted medicine. Not yet recruiting --> Recruiting